Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Oct;201(4):392.e1-5.
doi: 10.1016/j.ajog.2009.06.036. Epub 2009 Aug 29.

The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Cynthia Gyamfi  1 , Amanda L Horton, Valerija Momirova, Dwight J Rouse, Steve N Caritis, Alan M Peaceman, Anthony Sciscione, Paul J Meis, Catherine Y Spong, Mitchell Dombrowski, Baha Sibai, Michael W Varner, Jay D Iams, Brian M Mercer, Marshall W Carpenter, Julie Lo, Susan M Ramin, Mary Jo O'Sullivan, Menachem Miodovnik, Deborah Conway; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
Collaborators, Affiliations
Randomized Controlled Trial

The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Cynthia Gyamfi et al. Am J Obstet Gynecol. 2009 Oct.

Abstract

Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo.

Study design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo.

Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73).

Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rates of GDM among Treatment and Placebo Patients
See this image and copyright information in PMC

References

    1. Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol. 2001;15 Suppl 2:7–16. - PubMed
    1. Creasy RK. Preterm birth prevention: Where are we? Am J Obstet Gynecol. 1993;168:1223–1230. - PubMed
    1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–2385. - PubMed
    1. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419–424. - PubMed
    1. American College of Obstetricians and Gynecologists Committee Opinion. Use of progesterone to prevent preterm birth. Number 419, October 2008. Obstet Gynecol. 2008;112:963–965. - PubMed

Publication types

Grants and funding